What is the upside for SAGE Therapeutics'stock?
Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.
Where can I buy Sage Therapeutics stock?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sage Therapeutics' stock price today?
Where can I buy shares of Sage?
Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Will Sage Therapeutics stock go up?
The 20 analysts offering 12-month price forecasts for SAGE Therapeutics Inc have a median target of 54.50, with a high estimate of 105.00 and a low estimate of 36.00. The median estimate represents a +56.79% increase from the last price of 34.76.
Is SAGE Therapeutics Stock a good Buy?
Out of 11 analysts, 2 (18.18%) are recommending SAGE as a Strong Buy, 2 (18.18%) are recommending SAGE as a Buy, 7 (63.64%) are recommending SAGE as a Hold, 0 (0%) are recommending SAGE as a Sell, and 0 (0%) are recommending SAGE as a Strong Sell. What is SAGE's earnings growth forecast for 2022-2024?
Is SAGE Therapeutics profitable?
Earnings and Revenue History Growing Profit Margin: SAGE is currently unprofitable.
Why did SAGE stock drop?
SAGE, +1.81% tumbled 11.2% in premarket trading on Wednesday after Wall Street raised questions about the durability of the experimental treatment for major depressive disorder that Sage is developing with Biogen Inc. BIIB, -5.80% .
Why has SAGE share price dropped?
The firm said this was due to a decline in recurring business from existing customers, and a decrease in price on new contract licence.
What does Sage Therapeutics make?
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.
Should I buy or sell Sage Therapeutics stock right now?
17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently...
What is Sage Therapeutics' stock price forecast for 2022?
17 Wall Street analysts have issued twelve-month price objectives for Sage Therapeutics' stock. Their forecasts range from $37.00 to $85.00. On ave...
How has Sage Therapeutics' stock performed in 2022?
Sage Therapeutics' stock was trading at $42.54 on January 1st, 2022. Since then, SAGE shares have decreased by 18.7% and is now trading at $34.58....
When is Sage Therapeutics' next earnings date?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Sag...
How were Sage Therapeutics' earnings last quarter?
Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($2.07) EPS for the...
Who are Sage Therapeutics' key executives?
Sage Therapeutics' management team includes the following people: Mr. Barry E. Greene , Pres, CEO & Director (Age 59, Pay $1.25M) ( LinkedIn Pro...
Who are some of Sage Therapeutics' key competitors?
Some companies that are related to Sage Therapeutics include Grifols (GRFS) , Maravai LifeSciences (MRVI) , Legend Biotech (LEGN) , Sarepta The...
What other stocks do shareholders of Sage Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA) , A...
What is Sage Therapeutics' stock symbol?
Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
What is Sage Therapeutics?
When will Sage earnings call end?
(Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, reported business highlights and financial results for the third quarter ended September 30, 2021.
What is the Vickers top buyer and seller report?
SAGE earnings call for the period ending September 30, 2021.
When is Sage 2021?
Daily – Vickers Top Buyers & Sellers for 08/10/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is value investing?
(NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET.
Stock Price Forecast
Value investing is a factor-based investing strategy that involves picking stocks that you believe are trading for less than what they are intrinsically worth, usually by measuring the ratio of the stock's price to one or more fundamental business metrics. Zacks • 20 days ago.
Analyst Recommendations
The 20 analysts offering 12-month price forecasts for SAGE Therapeutics Inc have a median target of 60.50, with a high estimate of 105.00 and a low estimate of 42.00. The median estimate represents a +76.64% increase from the last price of 34.25.
When will Sage earnings call end?
The current consensus among 22 polled investment analysts is to Buy stock in SAGE Therapeutics Inc. This rating has held steady since November, when it was upgraded from a Hold rating. Move your mouse over past months for detail
Is the FDA accelerating the path through the clinic?
SAGE earnings call for the period ending September 30, 2021.
Is Phase 3 of the pharma trial positive?
The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.
Analyst price target for SAGE
The pharma company reported positive results from an important phase 3 trial.
SAGE earnings per share forecast
Based on 12 analyst s offering 12 month price targets for Sage Therapeutics Inc.
SAGE revenue forecast
What is SAGE 's earnings per share in the next 3 years based on estimates from 14 analyst s?
SAGE revenue growth forecast
What is SAGE 's revenue in the next 3 years based on estimates from 12 analyst s?
Sage Therapeutics Inc Stock Forecast
How is SAGE forecast to perform vs Biotechnology companies and vs the US market?
Will Sage Therapeutics Inc Stock Go Up Next Year?
Over the next 52 weeks, Sage Therapeutics Inc has on average historically risen by 31.5 % based on the past 6 years of stock performance.
Sage Therapeutics Inc Stock Price History
Over the next 52 weeks, Sage Therapeutics Inc has on average historically risen by 31.5% based on the past 6 years of stock performance.
Stock Predictions
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and SAGE is experiencing slight selling pressure.
SAGE : Sage Therapeutics stock forecast by Wall Street Analysts
Is Sage Therapeutics Inc stock public? Yes, Sage Therapeutics Inc is a publicly traded company.
Frequently Asked Questions about Sage Therapeutics stock forecast
The average Sage Therapeutics stock forecast from last 6 month is $71.44, and this show a -13.46% decrease in average from the prior price target of the each prediction. Also, this average forecast of $71.44 represents a -12.19% decrease from the past average forecast of $81.36, 6 months ago from 11 wall street analysts.
